

GLAXOSMITHKLINE PLC
Form 6-K
October 25, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 25 October 2017

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Philip Hampton
 - b) Position/status Non-Executive Chairman
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 July 2017 to 30 September 2017.
 - c) Price(s) and volume(s)

| Price(s) | Volume(s) |
|--------------------------|-----------|
| £15.18 | 2,882.082 |
| n/a (single transaction) | |
 - d) Aggregated information
Aggregated volume Price
 - e) Date of the transaction 2017-10-25
 - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Professor Sir Roy Anderson
 - b) Position/status Independent Non-Executive Director
 - c) Initial notification/
amendment Initial notification
- 2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 July 2017 to 30 September 2017.

- c) Price(s) and volume(s)

| | |
|--------------------------|-----------|
| Price(s) | Volume(s) |
| £15.18 | 473.485 |
| n/a (single transaction) | |

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2017-10-25
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr Vindi Banga
- b) Position/status Senior Independent Non-Executive Director

- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument

Ordinary shares of 25 pence
each ('Ordinary Shares')
ISIN: GB0009252882

| | | | |
|----|---------------------------|--|------------------------|
| b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 July 2017 to 30 September 2017. | |
| c) | Price(s) and volume(s) | Price(s) £15.18 | Volume(s) 1,893.939 |
| | Aggregated information | n/a (single transaction) | |
| d) | Aggregated volume Price | | |
| e) | Date of the transaction | 2017-10-25 | |
| f) | Place of the transaction | n/a | |

1. Details of PDMR/person closely associated with them ('PCA')

| | | |
|----|------------------------------------|------------------------------------|
| a) | Name | Dr Vivienne Cox |
| b) | Position/status | Independent Non-Executive Director |
| c) | Initial notification/ amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

| | | |
|----|------|----------------------|
| a) | Name | GlaxoSmithKline plc |
| b) | LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | | | |
|----|---|--|--|
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | |
| b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 | |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

July 2017 to 30 September
2017.

| | | | |
|----|---------------------------|--------------------------|----------------------|
| c) | Price(s) and volume(s) | Price(s) £15.18 | Volume(s) 349.967 |
| | | n/a (single transaction) | |

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2017-10-25

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms Lynn Elsenhans
Independent Non-Executive
b) Position/status Director

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

a) Description of the financial instrument American Depository Shares
(‘ADSs’)
ISIN: US37733W1053

b) Nature of the transaction Acquisition of notional ADSs
under the share allocation
arrangements for Independent
Non-Executive Directors for
the period of service from 1
July 2017 to 30 September
2017.

| | | | |
|----|---------------------------|--------------------------|------------------------|
| c) | Price(s) and volume(s) | Price(s) \$40.65 | Volume(s) 1,217.117 |
| | | n/a (single transaction) | |

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2017-10-25

- f) Place of the transaction n/a
-
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Dr Laurie Glimcher
- b) Position/status Independent Non-Executive Director
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument American Depository Shares ('ADSs')
ISIN: US37733W1053
- b) Nature of the transaction Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 September 2017 to 30 September 2017.
- c) Price(s) and volume(s) Price(s) Volume(s)
\$40.65 349.746
n/a (single transaction)
- d) Aggregated information
Aggregated volume Price
- e) Date of the transaction 2017-10-25
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Dr Jesse Goodman
- b) Position/status

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | |
|---|---|
| | Independent Non-Executive Director |
| c) Initial notification/ amendment | Initial notification |
| 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |
| 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |
| a) Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 |
| b) Nature of the transaction | Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 July 2017 to 30 September 2017. |
| c) Price(s) and volume(s) | Price(s) Volume(s) \$40.65 477.987 n/a (single transaction) |
| d) Aggregated information Aggregated volume Price | |
| e) Date of the transaction | 2017-10-25 |
| f) Place of the transaction | n/a |

| | |
|--|---------------------------------------|
| 1. Details of PDMR/person closely associated with them ('PCA') | |
| a) Name | Ms Judy Lewent |
| b) Position/status | Independent Non-Executive Director |
| c) Initial notification/ amendment | Initial notification |
| 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |
| 3. | |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|--|---|
| a) Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 |
| b) Nature of the transaction | Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 July 2017 to 30 September 2017. |
| c) Price(s) and volume(s) | Price(s) Volume(s) \$40.65 524.620 n/a (single transaction) |
| d) Aggregated information | |
| Aggregated volume Price | |
| e) Date of the transaction | 2017-10-25 |
| f) Place of the transaction | n/a |

1. Details of PDMR/person closely associated with them ('PCA')

| | |
|------------------------------------|------------------------------------|
| a) Name | Mr Urs Rohner |
| b) Position/status | Independent Non-Executive Director |
| c) Initial notification/ amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

| | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|--|---|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
| b) Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

for Independent
Non-Executive Directors for
the period of service from 1
July 2017 to 30 September
2017.

| | | |
|--|--------------------------|----------------------|
| c) Price(s) and volume(s) | Price(s) £15.18 | Volume(s) 473.485 |
| d) Aggregated information Aggregated volume Price | n/a (single transaction) | |
| e) Date of the transaction | 2017-10-25 | |
| f) Place of the transaction | n/a | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: October 25, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc